Roivant Sciences (NASDAQ:ROIV) PT Raised to $15.00
Roivant Sciences (NASDAQ:ROIV – Free Report) had its price objective increased by Deutsche Bank Aktiengesellschaft from $14.00 to $15.00 in a report released on Wednesday, Benzinga reports. They currently have a buy rating on the stock. ROIV has been the subject of several other reports. Piper Sandler started coverage on Roivant Sciences in a research […]